Biotech
Natera
Natera raises $200M Series E at $2.75B valuation
$200M
Total Raised
Series E
Latest Round
2003
Founded
2000+
Employees
San Carlos, CA
1 min read
Quick Facts
Valuation
$2.75B
Latest Round Size
$200M
Latest Round Date
July 2019
Natera: Series E Funding Round
Natera has successfully raised $200M in Series E funding, reaching a valuation of $2.75B.
Company Overview
Cell-free DNA testing for cancer and pregnancy
Funding Details
The Series E round was led by Perceptive Advisors, with participation from Goldman Sachs.
Company Information
- Headquarters: San Carlos, CA
- Founded: 2003
- Employees: 2000+
- Category: Biotech
Investment
Natera plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Perceptive Advisors: Verified investor in Series E
- Goldman Sachs: Verified investor in Series E
Key Investors
Perceptive Advisors
Lead Investor
Verified investor in Series E
Goldman Sachs
Investor
Verified investor in Series E
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min readβ’$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min readβ’$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min readβ’$250M